CI Investments Inc. cut its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 62.2% in the first quarter, Holdings Channel reports. The firm owned 23,379 shares of the exchange traded fund’s stock after selling 38,494 shares during the period. CI Investments Inc.’s holdings in SPDR S&P Biotech ETF were worth $2,986,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in XBI. Financial Life Planners acquired a new position in SPDR S&P Biotech ETF in the first quarter worth approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in SPDR S&P Biotech ETF during the fourth quarter valued at approximately $27,000. Intesa Sanpaolo Wealth Management acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $30,000. SHP Wealth Management acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $31,000. Finally, Legacy Wealth Managment LLC ID acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $32,000.
SPDR S&P Biotech ETF Stock Down 1.1%
XBI stock opened at $150.48 on Friday. The firm has a 50 day moving average of $144.24 and a two-hundred day moving average of $133.44. SPDR S&P Biotech ETF has a 12 month low of $84.39 and a 12 month high of $165.71. The company has a market capitalization of $10.30 billion, a price-to-earnings ratio of 11.47 and a beta of 0.82.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
